Acquired hemophilia A (AHA), a rare disease predominantly described in adults, has a reported incidence of 0.2-1.48 per million individuals [1, 2] . Pathophysiology is incompletely understood but involves autoantibodies to coagulation factor VIII. AHA has been associated with pregnancy, autoimmunity, malignancy, infection, post-autologous stem cell transplantation [2] , and following penicillin exposure [3] . AHA is unlike congenital hemophilia A in bleeding patterns. Patients with AHA may develop spontaneous, potentially life-threatening, soft tissue, muscle, and mucocutaneous bleeding, rather than hemarthroses; or they may exhibit mild or no bleeding symptoms. The autoantibodies exhibit nonlinear second-order kinetics, such that low but measurable factor VIII activity levels may coexist with major hemorrhage. Management options for bleeding patients include factor replacement to overcome low-titer inhibitors (<5 Bethesda units/mL, BU/mL), bypassing agents for high-titer inhibitor, and immunosuppression for inhibitor eradication [2] . Lupus anticoagulants (LACs) are pro-thrombotic autoantibodies that interfere with phospholipid and protein interactions [4] . Anti-prothrombin antiphospholipid antibodies are rare, but are associated with bleeding [4] . LACs are common in autoimmune disorders [4] . However, development of both AHA and LAC after allogeneic hematopoietic stem cell transplant (HSCT) in a pediatric setting has not been reported.
A ten-year-old Hispanic female with high-risk Philadelphia chromosome-like acute lymphoblastic leukemia in first complete remission (CR1) received conditioning with total body irradiation and cyclophosphamide followed by allogeneic HSCT utilizing 9/10 HLA mismatched (at the A allele) bone marrow. Transplant was preceded by multiple, aggressive cycles of chemotherapy, though remission was not achieved until blinatumomab was added to the treatment regimen. Post-HSCT course was complicated by acute and chronic gut, skin, and lung GVHD treated using local steroids (topical and buccal), systemic steroids, topical calcipotriene, and photopheresis, with a variable but overall poor response. Ruxolitinib was added to her GVHD treatment, with significant hepatotoxicity. She developed recurrent opportunistic bacteremias from her central line and chronic steroid use.
She was admitted 297 days after HSCT for persistent port-a-catheter site-associated Staphylococcus aureus bacteremia. Port-a-catheter removal with peripherally inserted central catheter replacement was planned. Pre-operative history revealed one episode of self-resolving epistaxis, but no other bleeding concerns. Laboratory testing included acutely decreased hemoglobin (8 g/dL), normal platelet count of 154,000/mm 3 , prolonged activated partial thromboplastin time (aPTT) of >130 s (normal 22.9-32.7), and a prothrombin time (PT) of 11.7 s (normal 9.6-11.6). Three months prior, her PT and aPTT were normal. Mixed aPTT partially corrected to 42 s. Relevant coagulation factor activity levels were normal except for factor VIII activity of 0.25%. Presence of an inhibitory autoantibody was confirmed and quantified at 10.2 BU/mL on heat inactivated plasma utilizing the Nijmegen modification of the Bethesda assay [5] . Notably, at the time this inhibitor was detected, the patient was receiving 1 mg/kg/day of oral steroids, with variable doses of oral steroids in the preceding five months, of up to 2 mg/kg/day. Complicating her pathology further Recombinant porcine factor VIII (rpFVIII; Obizur®, Shire) was chosen as surgical factor replacement, so that infused rpFVIII could be monitored and maintained at a hemostatic level, given her LAC. Inhibitor titer against rpFVIII prior to administration was 0.53 BU/mL. A test dose of rpFVIII (75 U/kg) was administered, demonstrating incremental recovery of 94% but diminished half-life. Therefore, a continuous infusion of rpFVIII was initiated preoperatively (loading dose: 180 U/kg, followed by a continuous infusion ranging between 50 and 100 units/kg/h) with a goal of Factor VIII levels >80% for 48 h after surgery. Figure 1 illustrates adequate rise in factor VIII levels with continuous rpFVIII infusion. In the 48 h post-operative period, she experienced no clinical bleeding, so the infusion was reduced to 10 units/kg/h targeting factor VIII levels >20% for an additional five days. She required larger than expected doses of rpFVIII, raising concern for increasing inhibitor titer to rpFVIII. Rituximab (375 mg/m 2 /dose/ week × 4) was then initiated to eliminate autoantibody production. At this time point, she was still receiving approximately 1 mg/kg/day of oral steroids. Figure 2 illustrates Factor VIII levels (Fig. 2a) and inhibitor titers (Fig. 2b) over the course of these interventions, highlighting improved endogenous factor VIII activity after the rituximab. Unfortunately, eight days after discontinuation of rpFVIII infusions, she developed fever, cellulitis, shoulder pain, and recurrent Staphylococcal bacteremia and shoulder magnetic resonance imaging confirmed osteomyelitis, but also a small intra-articular bleed. Her inhibitor level was 4 BU/mL at this time, with a nadir of 1.56 BU/mL at day 17 following development of AHA. No further inhibitor levels were checked. For <5 BU/mL, the inhibitor can be overcome with dosing standard human recombinant factor VIII (rfVIII). One dose of rfVIII was administered (100 units/ kg), and thereafter, she remained stable without further bleeding. After recovering from this bleed, the AHA eventually resolved, with normalization of her factor VIII activity levels. Further, her aPTT normalized when the AHA improved, suggesting resolution of the LAC. With intravenous antibiotics, she recovered from all infections. Unfortunately, she died four months later of complications from severe chronic lung GVHD (bronchiolitis obliterans).
We describe the first concurrent AHA and LAC in a pediatric HSCT patient. Development of coagulation factor auto-antibodies in a post-allogeneic transplant setting likely reflects a complex and rare phenomenon. AHA has been primarily reported in adults with autoimmune conditions, secondary autoimmune disorders after autologous HSCT, malignancies, or pregnancy [1, 2, 6] . AHA can be lifethreatening and delayed in diagnosis, both because of its rarity and because of its atypical manifestations compared to congenital hemophilia A 4 . Some patients with AHA have little or no bleeding; others present with severe hemorrhage either spontaneously or with childbirth, trauma or surgery. In this setting, rapid diagnosis and hemostatic treatment is critical. Adult AHA has a bimodal distribution, peaking between 20 and 30 years of age, then again at 68-80 years [7] . A LAC can complicate aPTT monitoring of coagulation status. Additionally, concern about a pro-thrombotic effect of a LAC complicates factor replacement [8] .
Ames et al. published a meta-analysis of adult cases (15 total) of combined AHA and LAC development [9] . Six Days from diagnosis Inhibitor titers Bethesda units/ml plasma b a Fig. 2 Factor VIII levels and factor VIII inhibitor titers. a At the time of diagnosis, factor VIII levels were very low, despite replacement with rfVIII, and quickly improved within days of rituximab therapy. b Contrary to factor VIII levels, inhibitor titers were very high at the time of diagnosis, but declined soon after treatment with rituximab (Color figure online) cases presented with thrombosis and complications related to pro-coagulopathy. Nine presented with bleeding and were associated with autoimmunity, monoclonal gammopathy, reactivation of Epstein Barr virus, and abortion after ovarian hyper-stimulation. Patients experienced bleeding cessation with Factor VIII, recombinant Factor VIIa a , or Factor VIII bypassing products, followed by immunosuppression (cyclophosphamide and steroid, rituximab, steroid alone, or steroid with concomitant intravenous immunoglobulin) [8] . Lozier et al. describes the only documented case of AHA in a 44-year old patient with sickle cell anemia after allogeneic HSCT with reduced-intensity conditioning. The patient was successfully treated with rpFVIII and rituximab [10] . This patient was found to have noninhibitory factor VIII-binding IgG antibodies in samples collected 2 years prior to the onset of AHA, which authors have noted to be found in 3-19% of normal people [11] [12] [13] . In contrast, at the time of bleeding the patient had IgG 4 antifactor VIII antibodies, which are well-described in AHA.
Our patient was unique in that she was young when she developed AHA and a LAC. Additionally, she was mildly symptomatic with one episode of epistaxis. No specific antibody subtype studies were conducted in our patient. However, her history of GVHD and alloreactivity likely contributed to the development of AHA and a LAC. We theorize that other ongoing comorbidities such as bacterial infection may have also played a role, but to an unknown extent.
The development of both AHA and LAC created a unique treatment challenges. We maintained hemostasis through a surgical intervention by treating with rpFVIII, which could be monitored, to target physiologic levels. In theory, infusing high dose factor VIII or bypassing agents (activated prothrombin complex concentrate or recombinant factor VIIa) could have accentuated a pro-thrombotic state associated with her LAC. We suggest that treatment of similar patients should be done with caution and vigilance for signs or symptoms of thrombosis. The decision to treat and eradicate the autoantibodies presented its own challenge. Although a viable option in other patients, cyclophosphamide might aggravate our patient's chronic hepatic injury or impede post-allogeneic HSCT immune reconstitution. This latter factor has paramount implications in a patient transplanted for malignancy, whose immune system may be providing a graft-vs. leukemia surveillance effect. Furthermore, she developed these complications while actively receiving steroids, considered a first line treatment option for AHA. Therefore, rituximab was chosen as the option with the strongest evidence to suggest efficacy.
This case report highlights the treatment challenges that can arise when a pediatric HSCT patient has multiple comorbidities including immune dysregulation, GVHD, and infection. Bleeding or abnormal coagulation studies must be investigated for evidence of AHA, a LAC, or other autoantibodies. We describe a successful approach to treating AHA and a LAC using initial large and continuous rpFVIII infusions with subsequent taper, accompanied by serial rituximab infusions.
